Randomized comparison of adjuvant Docetaxel / Cyclophosphamide with sequential adjuvant EC / Docetaxel chemotherapy in patients with HER2/neu negative early breast cancer.

Trial Profile

Randomized comparison of adjuvant Docetaxel / Cyclophosphamide with sequential adjuvant EC / Docetaxel chemotherapy in patients with HER2/neu negative early breast cancer.

Completed
Phase of Trial: Phase III

Latest Information Update: 30 Jun 2017

At a glance

  • Drugs Docetaxel (Primary) ; Cyclophosphamide; Epirubicin
  • Indications Early breast cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms PLAN B
  • Most Recent Events

    • 07 Jun 2017 Status changed from active, no longer recruiting to completed.
    • 02 Jun 2017 Results assessing final analysis of standard anthracycline-taxane based chemotherapy with 6 cycles of docetaxel/cyclophosphamide presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
    • 07 Jun 2016 Results assessing prognostic impact of RS, central grade, and IHC4 regarding long-term 5-year outcome presented at the 52nd Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top